The European Investment Bank provides €30 million loan to accelerate TB vaccine development

The European Investment Bank (EIB) agreed a €30 million loan with Vakzine Projekt Management GmbH (VPM), the German subsidiary of Serum Institute of India Pvt. Ltd. The loan will help VPM to perform the priMe trial. The priMe project contains a multicentre phase III double-blind, randomised, controlled study to evaluate the efficacy and safety of VPM1002 in comparison to the baccille Calmette–Guérin (BCG) vaccine. Vaccine research and development for the project will be carried out by VPM and the clinical trials will be scaled up in several high-burden sub-Saharan African countries.

For more information, read the full press release.

To subscribe to the Weekly Newsletter of new posts, enter your email here:

By TuBerculosis Vaccine Initiative (TBVI)

Published: Sept. 7, 2020, 1:21 p.m.

Last updated: Sept. 12, 2020, 12:35 p.m.

Print Share